Novartis

Novartis Releases 2016 Corporate Responsibility Performance Report

Article

Novartis has published its Corporate Responsibility (CR) Performance Report for 2016. This year’s report provides even more context on the company’s CR performance, as well as views and comments on trends and challenges within the healthcare industry. 

This is the fourth consecutive year Novartis has published an annual CR Performance Report. In 2016, we again structured our report in accordance with the Global Reporting Initiative’s (GRI) G4 guidelines, with disclosure at “comprehensive” level.

Novartis Joins Global Initiative to Fight the Rise of Noncommunicable Diseases

Novartis joins more than 20 leading biopharmaceutical companies to launch “Access Accelerated”, a global initiative to further advance access to prevention and care for noncommunicable diseases in low and lower-middle income countries
Press Release

January 18, 2016 /3BL Media/ - On January 18, 2017 at the World Economic Forum in Davos, Switzerland, Novartis joins more than 20 leading biopharmaceutical companies to launch “Access Accelerated”, a global initiative to further advance access to prevention and care for noncommunicable diseases (NCDs) in low and lower-middle income countries (LICs and LMICs).

Novartis Dialogue Explores Response to Chronic Illness in Poor Countries

Health experts from around the world met on November 29 to discuss ways to tackle an emerging crisis.
Press Release

December 14, 2016 /3BL Media/ - Chronic conditions such as heart disease and cancer are a growing threat in the world’s poorest countries and public health experts from around the world met on November 29 to explore ways of tackling this silent epidemic. Chronic conditions such as heart disease and cancer are a growing threat in the world’s poorest countries and public health experts from around the world met on November 29 to explore ways of tackling this silent epidemic.

Novartis Launches SMS for Life 2.0 in Nigeria to Help Improve Access to Essential Medicines

Summary: 
  • SMS for Life 2.0 launches for the first time in Kaduna State, Nigeria’s third most populous region, in collaboration with the Kaduna State Ministry of Health

  • Program uses smartphones and tablet computers to improve access to medicines and increase disease surveillance, helping to provide better care for patients

  • Initiative builds on the success of award-winning SMS for Life and will introduce eLearning for local healthcare workers
Press Release
  • SMS for Life 2.0 launches for the first time in Kaduna State, Nigeria’s third most populous region, in collaboration with the Kaduna State Ministry of Health

  • Program uses smartphones and tablet computers to improve access to medicines and increase disease surveillance, helping to provide better care for patients

  • Initiative builds on the success of award-winning SMS for Life and will introduce eLearning for local healthcare workers

Novartis Access Shares One-year Learnings and Announces Memorandum of Understanding with Rwanda

Summary: 
  • Rwanda becomes third country to launch Novartis Access portfolio against chronic diseases with first deliveries planned in early 2017
  • Since September 2015, Novartis Access has delivered more than 100,000 monthly treatments to Kenya, Ethiopia and Lebanon*
  • First-year learnings underline broader systemic issues in roll-out countries
Press Release
  • Rwanda becomes third country to launch Novartis Access portfolio against chronic diseases with first deliveries planned in early 2017
  • Since September 2015, Novartis Access has delivered more than 100,000 monthly treatments to Kenya, Ethiopia and Lebanon*
  • First-year learnings underline broader systemic issues in roll-out countries

Join the Webcast: Novartis Dialogue to Explore Solutions to the Rise of Chronic Diseases in the Developing World

The event “Improving care for chronic patients in lower-income countries: the patient journey,” will take place November 29, 2016.
Press Release

November 24, 2016 /3BL Media/ - The event “Improving care for chronic patients in lower-income countries: the patient journey,” will take place November 29, 2016.

Novartis Access and the Novartis Foundation will be discussing chronic diseases with experts from academia and non-profit organizations speaking and attending.

Novartis Improves Ranking in 2016 Access to Medicine Index

Summary: 
  • Novartis ranks third in 2016 ranking
  • Company tops the industry in access-to-medicine management and capacity building

  • Novartis integrated access strategy addressing all income segments stands out as best practice

Press Release
  • Novartis ranks third in 2016 ranking
  • Company tops the industry in access-to-medicine management and capacity building

  • Novartis integrated access strategy addressing all income segments stands out as best practice

Novartis Wins Two Prestigious Prix Galien Foundation Awards

Gleevec® recognized as “Discovery of the Decade” for Best Pharmaceutical Product, Cosentyx® as Best Biotechnology Product
Press Release

Basel, November 2, 2016 /3BL Media/ – Novartis has been awarded the prestigious 2016 Prix Galien USA Award for Best Biotechnology Product for Cosentyx® (secukinumab), as well as the Prix Galien Foundation “Discovery of the Decade” Award for Best Pharmaceutical Product for the drug Gleevec® (imatinib mesylate). The awards were presented at a ceremony in New York City.

Top Selling Pharmaceutical Companies Ranked According to Diversity in Executive Leadership

Press Release

HOUSTON, October 18, 2016 /3BL Media/ - The National Diversity Council is proud to present “Leading While Diverse: The Case for Diversity in Corporate Governance,” a comprehensive research report ranking top pharmaceutical companies based on their diversity in executive positions and boards of directors. The reputation of multinational pharmaceutical companies is currently one of the lowest, second only to health insurance companies.

Time to Talk about Partnerships for Access to Medicines

Opinion of Harald Nusser on www.sharedvalue.org
Blog

Access to healthcare is making controversial headlines these days as the report of the High-Level Panel on Access to Medicines set up by the Secretary-General of the United Nations was just released. We need to move away from ideological disputes about intellectual property and focus on how we can help patients receive the treatments they need now.

Any solution to the access challenge needs to consider the complex factors that affect access in developing countries. It would indeed be misleading and counter-productive to focus the access debate on patents. (...)

Pages

Subscribe to Novartis